Render Target: SSR
Render Timestamp: 2024-12-04T09:08:18.989Z
Commit: cd2fae6ca3f811b1ddb1df24ac291ed56d5d501b
XML generation date: 2024-09-20 06:19:14.384
Product last modified at: 2024-11-01T19:15:08.379Z
View Featured Offers >>
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72
  1. Products /
  2. Activators & Inhibitors /
  3. Imatinib

Imatinib #9084

    Product Information

    Product Usage Information

    Imatinib is supplied as a lyophilized powder. For a 10 mM stock, reconstitute the 5 mg in 847.9 μl DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 1-10 μM for 1-2 hours. Soluble in DMSO at 100 mg/ml; poorly soluble in ethanol. Soluble in water at 200 mg/ml.

    Storage

    Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 589.71 g/mol
    Purity >99%
    Molecular Formula C29H31N7O + CH4SO3
    CAS 220127-57-1
    Solubility Soluble in DMSO at 100mg/ml and H2O at 200mg/ml.

    Background

    Imatinib is a tyrosine kinase (TK) inhibitor that is a relatively specific ATP-binding site antagonist of Bcr-Abl, PDGF receptor, and c-Kit TKs (1-3). Results are encouraging in chronic myeloid leukemia (CML) clinical trials and imatinib has become a paradigm for targeted cancer therapeutics (4-6). Signal transduction through phospho-tyrosine pathways has been studied extensively, and tyrosine phosphorylation has been linked to multiple cell growth and differentiation pathways (7-9). Because the observed leukemic state of CML is dependent on the intact Bcr-Abl tyrosine kinase activity, extensive work has been done to identify substrates of Bcr-Abl and thus possible mechanisms leading to a myeloid expansion. Many groups have characterized prominent tyrosine-phosphorylated protein substrates in both CML blasts and Bcr-Abl-expressing cell lines, including SHIP, c-Cbl, Dok, Shc, and CrkL (10-15). In addition, key signal transduction pathways involving PI3 kinase, Ras, Myc, and Stat5 are also activated in a Bcr-Abl kinase-dependent manner (16).
    1. Buchdunger, E. et al. (1996) Cancer Res 56, 100-4.
    2. Heinrich, M.C. et al. (2000) Blood 96, 925-32.
    3. Druker, B.J. et al. (1996) Nat Med 2, 561-6.
    4. Mauro, M.J. and Druker, B.J. (2001) Curr Oncol Rep 3, 223-7.
    5. Druker, B.J. et al. (2001) N Engl J Med 344, 1031-7.
    6. Druker, B.J. et al. (2001) N Engl J Med 344, 1038-42.
    7. Blume-Jensen, P. and Hunter, T. (2001) Nature 411, 355-65.
    8. Ullrich, A. and Schlessinger, J. (1990) Cell 61, 203-12.
    9. Cantley, L.C. et al. (1991) Cell 64, 281-302.
    10. ten Hoeve, J. et al. (1994) Blood 84, 1731-6.
    11. Matsuguchi, T. et al. (1994) J Biol Chem 269, 5016-21.
    12. Carpino, N. et al. (1997) Cell 88, 197-204.
    13. Sattler, M. et al. (1997) Oncogene 15, 2379-84.
    14. Di Cristofano, A. et al. (1998) J Biol Chem 273, 4827-30.
    15. Wisniewski, D. et al. (1999) Blood 93, 2707-20.
    16. Kabarowski, J.H. and Witte, O.N. (2000) Stem Cells 18, 399-408.

    限制使用

    除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。

    专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    PathScan is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.